Molecular Partners AG (MOLN)
|Net Income (ttm)||-71.32M|
|Day's Range||19.16 - 19.48|
|52-Week Range||18.00 - 21.33|
|Est. Earnings Date||n/a|
Molecular Partners is a clinical stage biopharmaceutical company applying our pioneering DARPin® product candidates to treat serious diseases, with a current focus on infectious disease, oncology and ophthalmology. Our DARPin platform, which is designed using ankyrin repeat proteins, allows us to build product candidates with multiple mechanisms of action to address complex biological problems, while potentially offering patients products with higher efficacy and fewer adverse events. We believe that DARPin therapeutics represent a novel class... [Read more...]
In 2020, MOLN's revenue was 9.34 million, a decrease of -54.16% compared to the previous year's 20.38 million. Losses were -62.76 million, 73.0% more than in 2019.Financial numbers in millions CHFFinancial Statements
Molecular Partners Present Data Demonstrating Successful Inhibition of COVID19 Viral Variants with Ensovibep at the 2...
ZURICH-SCHLIEREN, Switzerland, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs kn...
ZURICH-SCHLIEREN, Switzerland, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN, NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs k...
-- Significant progress in COVID-19 trials, including positive results from healthy subjects and COVID-19 patients, supporting the launch of ongoing late-stage trials EMPATHY and ACTIV-3
AbbVie Inc (NYSE: ABBV) has terminated its license and collaboration agreement with Molecular Partners AG (NASDAQ: MOLN) for abicipar pegol for neovascular age-related macular degeneration (nAMD) and Di...
ZURICH-SCHLIEREN, Switzerland, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a...
Cowen & Co initiated coverage on Molecular Partners (NASDAQ: MOLN) with an Outperform rating and a Price Target of $50, implying an upside potential of more than 150%. The company and its partner Novart...
Molecular Partners Reports Continued Progress of Ensovibep Global Clinical Program; Positive in vitro Data Demonstrat...
ZURICH-SCHLIEREN, Switzerland, July 08, 2021 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR
Molecular Partners Announces Launch of American Depositary Shares (ADS) Offering in the United States
Molecular Partners AG (SIX:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it has commenced an initial pu...
Molecular Partners AG has filed to go public with an IPO on the NASDAQ.
While the focus in Switzerland, and elsewhere, has been primarily on vaccines in the past few months, a new medication may also offer hope in the fight against Covid-19. This is what we know about this ...
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients
Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients.